Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicify, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
|Original language||English (US)|
|Number of pages||3|
|State||Published - Sep 2007|
ASJC Scopus subject areas